Oncology Central

Olaparib becomes the first drug approved for BRCA breast cancer

0
The FDA has expanded the label for AstraZeneca’s oral PARP inhibitor Lynparza® (olaparib) to include the treatment of patients with metastatic breast cancer whose disease is associated with a BRCA gene mutation.

The decision makes olaparib the first and only approval for a PARP inhibitor for use beyond ovarian cancer. It is the first time any drug has been approved specifically to treat BRCA-mutated breast cancer.

The approval is a result of the highly promising results published from the

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.